Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22572959 | 0.81 | HTR2A (0.33) | HTR1AHTR6HRH3HTR1DCYP2D6 | |
| SCHEMBL4655460 | 0.74 | — | — | |
| SCHEMBL1559608 | 0.72 | HCAR2 (0.38) | — | |
| SCHEMBL4654505 | 0.71 | — | — | |
| SCHEMBL28249608 | 0.63 | HTR1A (0.37) | HTR1AHTR6HRH3HRH4HTR1D | |
| SCHEMBL16320684 | 0.63 | HTR1A (0.37) | HTR1AHTR6HRH3HRH4HTR1D | |
| SCHEMBL25247830 | 0.61 | HTR1A (0.53) | HTR1AHTR6MPOTSHR | |
| SCHEMBL19953546 | 0.60 | — | — | |
| SCHEMBL3161700 | 0.59 | GFER (0.54) | HTR1AHRH3CYP2D6TSHRMAOA | |
| SCHEMBL11133065 | 0.58 | KCNH2 (0.52) | HTR1AHRH3CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478687-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2024-03-20 | — | — | EP | disclosed |
| CN-109311896-B | Pyrazolopyrimidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2021-08-24 | — | — | CN | disclosed |
| CN-113135920-A | Pyrazolopyrimidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2021-07-20 | — | — | CN | disclosed |
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | MAP3K5, MAP3K2, MAPKAPK5 | HTR1A 4392/4885HTR6 2819/4885HRH3 2649/4885 |
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | MAP3K5, MAP3K2, MAPKAPK5 | HTR1A 4392/4885HTR6 2819/4885HRH3 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.